Dx & Vx
Business Services · United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
United StatesPhone Number
+61 269648770Website
www.dxvx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Dx & Vx
Dx&Vx specializes in the development of customized treatment strains and vaccines based on Multi-Omics technology. The company offers a range of healthcare business services including Chief Data Officer (CDO), Contract Research Organization (CRO), Contract Manufacturing Organization (CMO), and Chief Scientific Officer (CSO) services. Their intended clients include healthcare organizations and companies seeking advanced therapeutic solutions. Dx&Vx aims to enhance patient care through innovative and personalized healthcare solutions.Explore more
Dx & Vx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dx & Vx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Dx & Vx is spiking on competitors!
Earning: See what the market has to say on Dx & Vx recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Dx & Vx
Check if Dx & Vx has recently received funding, and reach out quickly before it becomes old news!
Dx & Vx, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Dx & Vx has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Dx & Vx launches new products
Click to see if Dx & Vx had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Dx & Vx
Find 2 more new buyers
Company Profile Activity
Activity Insights
Dx & Vx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dx & Vx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dx & Vx.
Dx & Vx Tech Stack
A closer look at the technologies used by Dx & Vx
See more technologies
Dx & Vx News & Media
Dx&Vx Accelerates Development of Universal COVID-19 Vaccine
Emerging as a next-generation vaccine amidst global resurgence of COVID-19 Expanding various pipelines other than universal COVID vaccine SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development...Dx&Vx, From mRNA Vaccines to Nanoparticle Vaccines era of Next-Generation Vaccines
Introduction of a Universal Coronavirus Vaccine: A robust cross-immunity effect to combat virus mutations. SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies. The accelerated approval and rapid distribution of mRNA vaccines introduced a new paradigm in infectious disease response, highlighting the need for swift action. Despite the success of mRNA vaccines, the unmet needs include limited effectiDX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology
Pioneering Korea's ARPA-H Project: Focused on mRNA Vaccine Room-Temperature Storage and Extra-Long-Term Preservation Creating a Platform for Prolonged Room-Temperature Storage and Efficient Distribution of mRNA Vaccines SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- On October 30, a Korean Biotech company, DX&VX(www.dxvx.com; KOSDAQ 180400, Majority shareholder Lim Chong-yoon) announced its selection as a co-research institution for Korea's first ARPA-H project, titled "STOREx: Stockpile TechnDX&VX is on Track and Accelerating the Development of Oral Obesity Treatment
Confirmation of effects compared to global late-stage clinical trials Accelerating the development of obesity treatment through early licensing out, global joint clinical trials, research funding investment, etc. SEOUL, South Korea, July 18, 2024 /PRNewswire/ -- DX&VX, which is gaining attention for developing an oral GLP-1 obesity treatment. The company is accelerating the optimization of new drug candidates. GLP-1 (glucagon-like peptide-1), an oral obesity treatment drug being developed by DX&
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Dx & Vx
Sign Up For FreeTo access detailed company insights
Dx&Vx specializes in the development of customized treatment strains and vaccines based on Multi-Omics technology. The company offers a range of healthcare business services including Chief Data Officer (CDO), Contract Research Organization (CRO), Contract Manufacturing Organization (CMO), and Chief Scientific Officer (CSO) services. Their intended... Read More
